Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Current Deferred Revenue (2016 - 2019)

Ultragenyx Pharmaceutical (RARE) has disclosed Current Deferred Revenue for 4 consecutive years, with $69000.0 as the latest value for Q1 2019.

  • Quarterly Current Deferred Revenue fell 90.46% to $69000.0 in Q1 2019 from the year-ago period, while the trailing twelve-month figure was $69000.0 through Mar 2019, down 90.46% year-over-year, with the annual reading at $6.0 million for FY2017, 1655.43% up from the prior year.
  • Current Deferred Revenue for Q1 2019 was $69000.0 at Ultragenyx Pharmaceutical, down from $1.2 million in the prior quarter.
  • The five-year high for Current Deferred Revenue was $6.0 million in Q4 2017, with the low at $69000.0 in Q1 2019.
  • Average Current Deferred Revenue over 4 years is $1.0 million, with a median of $637000.0 recorded in 2017.
  • The sharpest move saw Current Deferred Revenue skyrocketed 1655.43% in 2017, then plummeted 90.46% in 2019.
  • Over 4 years, Current Deferred Revenue stood at $341000.0 in 2016, then surged by 1655.43% to $6.0 million in 2017, then plummeted by 79.22% to $1.2 million in 2018, then plummeted by 94.45% to $69000.0 in 2019.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $69000.0, $1.2 million, and $723000.0 for Q1 2019, Q2 2018, and Q1 2018 respectively.